Biomarkers Are Growing Fast but Not at the Same Speed Everywhere

The next phase of biomarker growth will depend less on discovering signals and more on proving, scaling, and deploying them across very different healthcare systems.

The most interesting story in biomarkers is not that the market is getting bigger. It is that different parts of the market are moving at different speeds.

Next Move Strategy Consulting projects the global Biomarkers Market to rise from $67.70 billion in 2024 to $133.51 billion by 2030, equivalent to an 11.9% CAGR between 2025 and 2030. But at the regional level, the report expects North America to retain its current leadership while Asia-Pacific remains the fastest-growing region. That contrast matters because it points to two different sources of competitive advantage: established clinical and regulatory infrastructure in one market, and faster adoption of emerging technologies in another.

Data sourced from Next Move Strategy Consulting, “Biomarkers Market”.

***Request for a FREE Sample Right Now!***

That is where the market becomes more complicated and more interesting.

The market is nearly doubling, but the real prize is clinical adoption

A move from $67.70 billion to $133.51 billion represents an increase of about $65.81 billion, or roughly 97% growth over the forecast period. Put differently, the industry is expected to finish 2030 at almost 1.97 times its 2024 size. The reported 11.9% annual growth rate therefore is not a small incremental expansion; sustained at that pace, it fundamentally changes the scale of the opportunity.

Yet market expansion does not automatically mean every biomarker becomes clinically valuable.

A biomarker still has to move through a difficult chain: discovery, analytical validation, clinical validation, regulatory acceptance, reimbursement considerations, workflow integration, and eventual use by physicians or patients. The U.S. Food and Drug Administration’s Biomarker Qualification Program explicitly focuses on whether a biomarker is reliable and appropriate for a clearly defined context of use in drug development.

That distinction changes how the headline forecast should be read. The opportunity is not merely in producing more biomarker data. It is in turning that data into a dependable decision-making tool.

Five segment lenses show where the competition is forming

The report divides the market across product and services, biomarker type, technology, disease indication, application, end user, and geography. While the publicly available report page does not provide a complete revenue ranking for every segment, five particularly important strategic lenses stand out.

Technology is one. The market spans immunoassays, next-generation sequencing, PCR, mass spectrometry, and chromatography. The coexistence of these methods is important: the future of biomarkers is unlikely to belong to one universal testing technology. Different clinical questions require different combinations of sensitivity, specificity, cost, speed, and sample requirements.

Disease indication is another. Cancer is joined by infectious, immunological, neurological, and cardiovascular diseases. This broadens the addressable market beyond oncology and creates room for disease-specific biomarker strategies.

Application is equally significant, spanning diagnostics, drug discovery and development, and personalized medicine. The same biological signal can therefore generate value at multiple points in the healthcare value chain.

Biomarker type also matters. Safety, efficacy, and validation categories include predictive, surrogate, pharmacodynamic, and prognostic applications, showing that biomarkers can influence not only diagnosis but also how therapies are developed and evaluated.

Finally, product and services separates consumables, services, and software — an indication that the commercial opportunity is broader than test kits alone.

The strategic takeaway is that companies should avoid thinking about the category as a single product market. It is closer to an ecosystem where assays, instruments, analytics, software, clinical evidence, and laboratory workflows increasingly intersect.

Chronic disease creates demand but evidence determines who captures it

The report identifies the rising burden of chronic disease as a major growth driver, alongside greater biomarker use in drug development and clinical trials and advances in imaging technology.

The underlying healthcare pressure is substantial. The World Health Organization says noncommunicable diseases account for about 41 million deaths annually, with cardiovascular disease, cancer, and other chronic conditions representing a major share of the global burden. Detection, screening, and treatment are central components of the response.

For biomarker developers, however, rising disease burden is only the starting point.

The harder question is whether a test changes what happens next. Research published through the National Cancer Institute’s Early Detection Research Network emphasizes that a biomarker intended for routine care needs to demonstrate clinical utility not merely strong analytical performance. In practice, that means the result should lead to a clinical action that improves a patient-relevant outcome.

That is an important filter for investors. A large patient population can create an attractive theoretical market, but a biomarker with weak evidence, unclear actionability, or poor integration into care pathways can struggle to turn scientific promise into recurring commercial demand.

AI may accelerate discovery but it does not remove the proof problem

The report positions AI-driven biomarker diagnostics as a major future opportunity and points to applications in drug discovery, diagnostics, and personalized medicine. It also highlights the increasing use of AI and advanced analytical techniques in biomarker development.

The temptation is to assume that better algorithms automatically produce better biomarkers.

They do not.

AI can improve pattern recognition, candidate discovery, and the analysis of large biological datasets, but the resulting biomarker still needs to be reproducible, clinically meaningful, and usable in real-world settings. Regulatory systems are increasingly focused on evidence around intended use, performance, and reliability.

This creates an interesting division of labor. Algorithms may shorten the path from raw data to a promising candidate, while validation remains the slower and more expensive part of the journey.

My read of the data is that this could shift investment toward companies that own the entire evidence chain rather than those with the flashiest discovery technology alone. That is an inference from the market dynamics, not a forecast stated by the report.

North America and Asia-Pacific represent two different growth playbooks

North America currently dominates the market and is expected to maintain that position throughout the forecast period. The report connects this leadership to strong biomarker adoption, early disease detection, and developments around diagnostic testing.

At the same time, Asia-Pacific is identified as the fastest-growing region, with the report highlighting AI-enabled approaches to biomarker discovery and cancer drug development.

This is the counterintuitive part of the market.

The largest market is not necessarily the fastest-moving market.

For a global company, that means the North American strategy may emphasize evidence, regulatory pathways, clinical adoption, and established laboratory infrastructure, while an Asia-Pacific strategy may place more weight on technology partnerships, local clinical ecosystems, and scalable deployment.

Regulation adds another layer. In the United States, FDA policy around laboratory-developed tests has been evolving materially. The agency’s current information notes that a 2024 final rule was later vacated by a federal district court, followed by a September 2025 rule reverting the relevant regulatory language.

For biomarker developers, regulatory strategy is therefore not an administrative afterthought. It can influence development timelines, evidence requirements, commercialization models, and the attractiveness of different testing approaches.

The high cost of development may become the market’s hidden gatekeeper

The report identifies the cost of biomarker development as a major restraint. Discovery is only one expense. Validation, regulatory work, clinical studies, infrastructure, and standardization can all increase the cost of turning a promising marker into a usable product.

This matters especially as the industry moves toward multi-biomarker panels and multi-omics approaches.

A broader panel can potentially provide richer biological information, but it can also create more complicated questions around assay consistency, data interpretation, cost, and standardization. The report specifically highlights scalability, cost-effectiveness, and standardization as challenges for comprehensive biomarker panels.

For someone working in biomarker development this year, the practical implication is straightforward: a technically impressive panel is not enough. Development teams have to think about sample collection, turnaround time, reproducibility, reporting, clinician usability, and the evidence needed to justify real-world adoption from the beginning.

That changes the definition of a good product.

The winner may not be the test that detects the greatest number of signals. It may be the test that generates the most actionable information with the least friction.

The competitive field is converging around platforms, not isolated assays

The report profiles a broad group of companies, including F. Hoffmann-La Roche, Abbott Laboratories, Thermo Fisher Scientific, Johnson & Johnson, Siemens Healthcare, Merck, Qiagen, Agilent Technologies, Bio-Rad Laboratories, and Revvity, among others.

The mix is revealing. It includes diagnostics companies, life-science technology providers, pharmaceutical businesses, and research-service organizations.

That suggests the biomarker economy is becoming increasingly interconnected.

The report highlights developments involving AI-powered pathology, blood-based biomarkers, NGS-based oncology testing, digital biomarkers, and multiplex technologies.

The common theme is convergence. Biomarkers increasingly sit at the intersection of diagnostics, drug development, software, data science, pathology, and precision medicine.

That makes partnerships strategically important but it also raises the bar for execution. A biomarker company may need capabilities far beyond biological discovery to build a durable commercial position.

What happens next may be decided after discovery, not before it

The obvious narrative is that biomarker growth will continue because chronic disease is increasing, precision medicine is expanding, and AI is improving discovery.

I think that is incomplete.

The next phase is more likely to be defined by translation: which biomarkers can survive the journey from scientific signal to standardized test to clinical decision to scalable business?

The report’s forecast points to a market approaching twice its 2024 size by 2030. But the most valuable companies may not simply be those participating in the largest segment or fastest-growing geography. My view is that the strongest positions will belong to organizations that can combine biological insight with validation, regulatory readiness, workflow integration, and economic practicality.

In other words, the industry’s next competitive battle may be less about discovering another promising biomarker and more about proving that it deserves to become part of routine care.

That is where the market’s nearly $66 billion incremental opportunity could become much more than a forecast.